What Asenza Plus treats: Main Uses and Benefits

Asenza Plus is a combination medication applied in addressing conditions characterized by periods of heightened symptoms related to systemic imbalance. Its core therapeutic use is as an adjunct to diet and exercise to improve glycemic control in adult patients with Type 2 Diabetes Mellitus. The drug is commonly used across conditions presenting with acute episodes when short-term symptomatic assistance is needed.

---

This combination therapy is commonly used to help with symptoms that create noticeable physiological strain in those who require additional support. The primary therapeutic contexts include its use as an adjunct to diet and exercise, and in situations where symptoms become temporarily overwhelming. The indication for this product includes improving glycemic control.

---

This approach supports patients during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms. It may assist with maintaining functional stability and helps improve day-to-day comfort.

“This therapeutic approach is relevant when supportive symptom management is appropriate.”

Quick Fact: Relevant for Symptoms that Interfere with Daily Functioning

Regulatory References

1. Philippine FDA drug information

Who can and cannot use Asenza Plus?

Eligibility for Asenza Plus (Glimepiride/Pioglitazone) is strictly determined by regulatory standards, with use limited to adult patients aged 18 years or older with Type 2 Diabetes Mellitus. Use is not recommended in pediatric patients as safety and efficacy have not been established.

The medicine is contraindicated and must not be used in several patient groups, including those with:

• Established New York Heart Association (NYHA) Class III or IV heart failure or a history of cardiac failure.
• Active liver disease or significantly elevated liver enzymes.
• Active bladder cancer or Type 1 Diabetes Mellitus.
• Known hypersensitivity to Pioglitazone, Glimepiride, or other sulfonamide derivatives.
• Severe renal function disorders (creatinine clearance less than 30 ml/min).

Use is also contraindicated during pregnancy and not recommended during breastfeeding. Patients with pre-existing conditions like NYHA Class I or II heart failure or a history of bladder cancer require specific caution and close clinical monitoring.

Asenza Plus contains a combination of Aceclofenac (a Non-Steroidal Anti-Inflammatory Drug or NSAID), Paracetamol (Acetaminophen), and Serratiopeptidase, and therefore may interact with several other medications. It is crucial to inform your healthcare provider about all medicines, over-the-counter products, and herbal supplements you are currently taking.

Major Interactions

Medicine Type	Potential Effect	Recommendation
Anticoagulants/Antiplatelet Agents (e.g., Warfarin, Aspirin)	Increased risk of bleeding or hemorrhage due to effects from both Aceclofenac and Serratiopeptidase.	Close monitoring of blood clotting parameters (INR) and potential dose adjustment is necessary.
Other NSAIDs or Painkillers (e.g., Ibuprofen, Diclofenac, Nimesulide)	Increased risk of gastrointestinal side effects, including ulceration or bleeding. Avoid concomitant use to prevent additive adverse effects.	Avoid combination.
Alcohol	Concurrent use, particularly in chronic or excessive amounts, significantly increases the risk of liver damage due to the Paracetamol component.	Avoid alcohol consumption.

---

Other Notable Interactions

• Diuretics and Antihypertensives (e.g., ACE inhibitors, Angiotensin II Antagonists): Aceclofenac may reduce the effectiveness of these blood pressure lowering medications and increase the risk of kidney damage.
• Lithium and Digoxin: Aceclofenac can increase the blood levels of these drugs, potentially leading to toxicity. Monitoring is required.
• Selective Serotonin Reuptake Inhibitors (SSRIs): When combined with Aceclofenac, the risk of gastrointestinal bleeding is increased.
• Antidiabetic Agents: NSAIDs like Aceclofenac may increase the risk of hypoglycemia (low blood sugar), requiring monitoring and possible dosage adjustment of the diabetes medication.

This is not a complete list. Always consult with your doctor or pharmacist to assess potential interactions based on your complete medical history and current regimen.

Asenza Plus is a fixed-dose combination containing Pioglitazone and Glimepiride, each acting on distinct biological pathways to modulate glucose homeostasis.

Pioglitazone functions as a highly selective agonist for Peroxisome Proliferator-Activated Receptor-gamma (PPARgamma), a nuclear receptor primarily expressed in adipose tissue, skeletal muscle, and liver. Binding and activation of PPARgamma initiates changes in gene transcription, modulating the expression of insulin-responsive genes involved in glucose and lipid metabolism. This intracellular cascade leads to a decrease in peripheral and hepatic insulin resistance, resulting in enhanced insulin-dependent glucose disposal in peripheral tissues and reduced hepatic glucose output. Pioglitazone's action requires the presence of endogenous or exogenous insulin.

Glimepiride is a sulfonylurea agent that targets the sulfonylurea receptor 1 (SUR1) subunit of the ATP-sensitive potassium (KATP) channel on the pancreatic beta-cell membrane. Its interaction with SUR1 inhibits the KATP channel, preventing potassium efflux and causing beta-cell membrane depolarization. This depolarization opens voltage-dependent L-type calcium channels, increasing intracellular calcium concentration. The resulting surge in cytosolic calcium triggers the exocytosis of insulin-containing granules, stimulating the release of insulin into the systemic circulation. Glimepiride also exhibits extrapancreatic effects, potentially increasing the sensitivity of peripheral tissues to insulin.

The use of the Pioglitazone and Glimepiride fixed-dose combination, often referred to by the brand name Asenza Plus, follows specific clinical protocols. The medication is administered strictly via the oral route.

---

Administration Protocol and Dosing Constraints

The standard dosing protocol involves a single tablet once daily, which must be taken with the first main meal of the day. Initial dosage is individually determined based on the patient's existing therapeutic regimen, typically starting at 30 mg/2 mg or 30 mg/4 mg per day. The total daily intake of the fixed combination must not exceed 45 mg of Pioglitazone and 8 mg of Glimepiride. Subsequent adjustments are made gradually, and the medicine is intended for long-term use as a maintenance therapy.

---

Special Procedural Conditions

Administration involves specific timing constraints: the tablet must be taken at least four hours prior to coadministration with Colesevelam. If a strong CYP2C8 inhibitor is being taken concurrently, the patient must be switched to the individual component tablets, as the resulting Pioglitazone dose limit is lower than the available fixed-dose strengths. This product is not recommended for use in pediatric patients. For older adults or those with renal impairment, dose selection must be approached conservatively. If a dose is missed, the standard procedure is to skip the missed dose and resume the normal daily schedule rather than taking a double dose.

Research evidence / Overview of studies for Asenza Plus

1. Evidence for Use in Type 2 Diabetes Mellitus

The primary research for the combination of Glimepiride and Pioglitazone has been conducted using Randomized Controlled Trials (RCTs). These short-term studies were used in research exploring how blood sugar markers change over defined periods in adults with Type 2 Diabetes Mellitus (T2DM). The studies monitored populations whose blood sugar control was reported as not meeting targets while they were on existing single-agent treatment.

Research examined core markers of glycemic control, such as changes in Glycosylated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG). Studies also explored outcomes related to systemic or functional imbalance, such as patterns in lipid profiles and measures related to insulin sensitivity. Data show patterns related to glycemic control; studies tracking these markers described measurable changes in HbA1c and FPG over the observation periods in the observed populations.

2. Comparative and Foundational Research

Studies were also conducted to evaluate how the combination was observed when compared against single agents or placebo in trials. This comparative research provides insight into how blood sugar and metabolic markers evolved in different groups under controlled conditions.

Furthermore, the fixed-dose tablet format of Asenza Plus was evaluated in research required by regulators. Research examined specific bioequivalence studies using healthy volunteers. Data show patterns related to bioequivalence; the fixed-dose tablet was observed to be comparable to the individual components administered simultaneously.

3. Long-Term Studies and Follow-Up

The evidence base includes intermediate and long-term research, which was studied for the durability of blood sugar control. While many initial trials are short-term, some studies were observed in periods extending up to 5 years or more. However, evidence is limited, and the combination's long-term effects on complex cardiovascular outcomes, such as major events, are not fully established.

4. What Research is Still Needed

Research is ongoing, but evidence highlights what is known and what is still uncertain. Long-term effects are not fully established for the fixed-dose combination product itself. Data for certain groups, such as pediatric patients or those with severe underlying health conditions, remain insufficient, and more research is needed to provide insight into outcomes across diverse or specific comorbidity profiles.

Common questions about Asenza Plus (FAQ)

---

Q: How quickly does Asenza Plus usually start working?

According to official product information, the active ingredient Pioglitazone is measurable in the blood within 30 minutes, with peak concentrations typically reached in about two hours. While the components become active relatively quickly, the full effect on long-term blood sugar markers is observed over time, with steady-state concentrations generally achieved in about seven days.

---

Q: Is it normal to feel a little dizzy after taking Asenza Plus?

Yes, regulatory documents list dizziness as a reported side effect associated with the use of this fixed-dose combination. This information is derived from official product data.

---

Q: Can I take Asenza Plus if I have a history of liver issues?

The medicine is contraindicated (meaning it must not be used) in patients with active liver disease or significantly elevated liver enzymes. Prior to starting treatment, liver tests are typically obtained. Regulatory documents state that caution is warranted and that the situation should be managed appropriately if prior liver issues are a factor.

---

Q: Does Asenza Plus cause weight gain or weight loss?

The Pioglitazone component of the drug is commonly associated with weight gain, which may be related to fluid retention or an increase in fat mass, as documented in official labeling. Weight gain is the pattern most often noted in regulatory summaries, and is a factor monitored by prescribers.

---

Q: Are there any common foods or drinks that interact with Asenza Plus?

Official labeling advises that alcohol consumption should be limited due to the potential increased risk of low blood sugar (hypoglycemia) caused by the Glimepiride component. The tablet is described in official documents as being taken with the first main meal of the day.

---

Q: Can I take Asenza Plus with over-the-counter pain relievers like ibuprofen?

The use of certain non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may potentially increase the risk of low blood sugar (hypoglycemia) due to the Glimepiride component. This potential is noted in warnings about drug interactions for the components.

---

Q: What kind of monitoring is typically done when a person is taking Asenza Plus?

Monitoring typically includes obtaining liver tests before treatment begins. Additionally, patients are closely observed for signs of fluid retention, weight gain, and symptoms related to congestive heart failure, as these are documented risks associated with the Pioglitazone component.

---

Q: Does Asenza Plus affect birth control pills?

Official labeling notes that the Pioglitazone component may cause some premenopausal women who do not have regular menstrual periods to ovulate. This means that, in some cases, the medication could increase the chance of pregnancy for women in this group.

---

Q: What happens if I miss a dose of Asenza Plus?

Regulatory documents describe the protocol for a missed dose as skipping it and resuming the normal daily schedule. This instruction is designed to help avoid the potential risk of an excessive drop in blood sugar (hypoglycemia) or exceeding the established maximum daily dosage.

---

Q: Is the evidence for Asenza Plus considered strong by regulatory bodies?

The fixed-dose combination was approved by regulatory bodies based on data from Randomized Controlled Trials (RCTs) and bioequivalence studies which examined its use in adults with Type 2 Diabetes Mellitus.

---

Q: Why are there different strengths of Asenza Plus?

The different strengths are available to allow for individualized initial dosing based on a patient's existing treatment regimen and specific metabolic needs. The goal of this design is to support the prescriber in individualizing therapy while staying within the established maximum daily amounts of the components.

---

Q: Does taking Asenza Plus with food make a difference?

While the requirement to take the tablet with a meal is stated in official directions, pharmacokinetic studies indicate that food is not generally expected to change the overall absorption of either active ingredient. It may, however, slightly delay the time it takes for the Pioglitazone component to reach its maximum concentration in the blood.

---

Q: Is there a generic version of Asenza Plus available?

Yes, the fixed-dose combination of the active ingredients, Pioglitazone and Glimepiride, is generally available under generic names following regulatory approval and patent expiration on the original brand product.

---

Q: Does Asenza Plus affect my ability to drive or operate machinery?

The risk of extremely low or high blood sugar (hypoglycemia or hyperglycemia) can cause effects such as dizziness, drowsiness, or blurred vision. Official warnings describe that these effects may impair a patient's ability to drive or operate machinery.

---

Q: Do older adults (seniors) need to take a lower amount of Asenza Plus?

Official documentation states that older adult patients are recognized as having an increased risk for low blood sugar (hypoglycemia). Due to this risk, dose selection and titration in this population are approached with caution, and close monitoring is necessary.

---

Q: Can Asenza Plus cause skin reactions or rashes?

Official documents list skin-related effects, including rash and itching skin, as possible side effects associated with the drug. The Glimepiride component is also associated with a rare but serious risk of hypersensitivity reactions.

---

Q: What does 'Plus' mean in the drug name Asenza Plus?

The term 'Plus' in the name indicates that the medicine is a Fixed-Dose Combination (FDC) product. This means the tablet contains two distinct active ingredients, Pioglitazone and Glimepiride, combined into a single dosage form.

---

Q: Does Asenza Plus interact with herbal supplements like St. John's Wort?

The use of certain herbal supplements known to affect drug metabolism in the liver, such as St. John's Wort, may impact the levels of the active ingredients in the body. This could potentially lead to a reduction in the overall effectiveness of the medication.

---

Q: Can Asenza Plus affect blood pressure readings?

The Pioglitazone component can cause fluid retention which may lead to or worsen conditions such as Congestive Heart Failure. Patients are monitored for signs of fluid retention and related cardiac symptoms, which are often connected to blood pressure.

---

Q: Is Asenza Plus used in combination with any other medicines?

The fixed-dose combination is officially indicated to improve blood sugar control in adults with Type 2 Diabetes Mellitus who are not adequately controlled on a single agent. Official documents also provide warnings concerning the drug's safety when it is used in combination with other antidiabetic agents, such as insulin, particularly regarding the risk of hypoglycemia.

Official Storage and Disposal Instructions

Labeled Storage Temperature Requirements:	Not exceeding 30 C or room temperature [1, 2].
Protection Requirements:	Must be kept away from excess heat, moisture, and direct light [2, 3].
Handling Prohibition:	Keep from freezing [2].
Packaging Rules:	Store in the original container and ensure it is closed for protection [1, 3].
Child-Safety Storage:	Must be kept out of the sight and reach of children [1, 3].
Disposal Instructions:	Dispose of any unused medicinal product or waste material according to local requirements [1]. Do not keep outdated medicine [2].

Regulatory documents mandate that Asenza Plus tablets be stored under controlled conditions to maintain product integrity. This requires storage at room temperature, protected from light and moisture, and explicitly prohibits freezing or exposure to excessive heat. Furthermore, the official labeling includes non-negotiable child-safety rules and requires that disposal of unused or expired tablets adhere strictly to local, regulated guidelines.